The myeloprotective effect of high dose medroxyprogesterone acetate (HD-MPA) in patients with carcinoma of the uterine cervix (stage II & III) treated by radiation.
Sangruchi
S
S
Department of Radiology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
D000284:Administration, Oral; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage* / Q000627:therapeutic use; D004311:Double-Blind Method; D005260:Female; D006400:Hematocrit; D006801:Humans; D007958:Leukocyte Count; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage* / Q000627:therapeutic use; D011446:Prospective Studies; D002583:Uterine Cervical Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000532:radiotherapy; D015430:Weight Gain
D018931:Antineoplastic Agents, Hormonal; D017258:Medroxyprogesterone Acetate